skip to content


'Abzena inside' product enters phase II trial

06 March 2017 07:47

Abzena has noted that one of the the 'Abzena inside' Composite Human Antibody products previously disclosed as being in phase I trials is moving forwards into a phase II clinical trial.

The product is being developed by an un-named major US pharmaceutical company for the treatment of neurodegenerative conditions and has been studied to date in two phase I clinical trials.

Chief executive Dr John Burt, Abzena said: "We are pleased to see the progression of this 'Abzena inside' product into phase II clinical development following the recent similar announcements about two other 'Abzena inside' products.

"This illustrates the strength we have in the portfolio of products that our partners are developing based on our antibody engineering technology."

Story provided by

Related Company: ABZA

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

aew-banner-180x255.jpg -

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.